Results 31 to 40 of about 29,806 (309)

Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]

, 2017
BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Farinati, Fabio, Ferrarese, Alberto, Forton, Dm, Franceschet, E, Gambato, M, Germani, Giacomo, Mescoli, Claudia, Romano, Antonietta, Rugge, Massimo, Russo, FRANCESCO PAOLO, Senzolo, Marco, Shalaby, S, Vitale, A, Zanetto, Alberto   +16 more
core   +1 more source

Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience

Annals of Hepatology, 2019
Introduction and aim: Recurrent HCV infection after liver transplant (LT) has a negative impact on graft and patient survival. The aim of this study is to describe the efficacy and safety of sofosbuvir (SOF-based) regimens in the treatment of recurrent ...
Alexandre Araujo, Vanessa Valenzuela-Granados, Antonio B. Lopes, Matheus T. Michalczuk, Augusto Mantovani, Mario R. Alvares-da-Silva   +5 more
doaj   +1 more source

Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]

, 2014
Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS, Ford, N, Fortunak, J, Hill, A, Khoo, S, Simmons, B, van der Ven, N   +6 more
core   +2 more sources

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients

Nefrología (English Edition), 2017
Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection.
Soraya Abad, Almudena Vega, Diego Rincón, Eduardo Hernández, Evangelina Mérida, Nicolás Macías, Raquel Muñoz, Mónica Milla, Jose Luño, Juan Manuel López-Gómez   +9 more
doaj   +1 more source

Chronic Hepatitis C Treatment with New Antiviral Agents

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018
Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed.
Özlem KANDEMİR
doaj   +1 more source

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Update on hepatitis C: Direct-acting antivirals

World Journal of Hepatology, 2015
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert, Ryan B, Perumpail, Aijaz, Ahmed   +2 more
openaire   +2 more sources

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study [PDF]

, 2018
AIM: To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Russo, Francesco Paolo, Senzolo, Marco, Shalaby, Sarah, Zanetto, Alberto, Zanus, Giacomo   +10 more
core   +1 more source

Retreatment Options Following HCV Direct-Acting Antiviral Failure [PDF]

Current Treatment Options in Infectious Diseases, 2017
Despite the excellent efficacy of direct acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug resistance, and lack of data regarding retreatment.
Autumn, Zuckerman, Cody A, Chastain, Susanna, Naggie   +2 more
openaire   +2 more sources

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

Annals of Hepatology, 2017
Introduction: Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to ...
Curtis L. Cooper, Holly Hatashita, Daniel J. Corsi, Parmvir Parmar, Raymond Corrin, Gary Garber   +5 more
doaj   +1 more source